Prospective Observational Study on Pharmacological Voluntary Termination of Pregnancy: Predictors of Pelvic Pain During Treatment
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 2
- 主要终点
- Pain symptoms of patients undergoing pharmacological IVG
研究概览
简要总结
Pharmacological treatment for voluntary termination of pregnancy is a safe and effective practice, but has as its limitation a greater need for analgesic coverage than surgical treatment. Despite this, to date there are no specific guidelines on the management of pain therapy during pharmacological voluntary termination of pregnancy and in particular on its correlation with gestational age at the time of treatment. The aim of the study is to investigate the correlation between the pain symptoms reported by the patients and the gestational age at the time of the pharmacological voluntary interruption of pregnancy and to identify the presence of possible predictive factors, in order to be able to outline the correct therapeutic management.
详细描述
According to the Law 194 of 1978, in Italy the voluntary interruption of pregnancy (IVG) can be requested by the woman within the first 90 days of gestation for health reasons, economic, social or family. Voluntary termination of pregnancy may be achieved by surgical or pharmacological treatment.
The surgical treatment involves hysteroaspiration associated with instrumental revision of uterine cavity (RCU).
The drug treatment involves administration of mifepristone (known as RU486), followed by approximately 48 hours after administration of prostaglandins. The World Health Organization in a 2003 publication, updated in 2012, has indicated mifepristone as one of the pharmacological treatments for IVG in the first 9 weeks of gestation. Since July 2009, the AIFA has authorised its marketing in Italy. The choice between the two treatments depends on the gestational age and the patient's preferences, after careful counselling with the gynecologist, about the risks and benefits of both procedures.
In particular, until a few months ago, pharmacological treatment was reserved in Italy exclusively for patients who required IVG within the 49° day of amenorrhea. Beyond this threshold, and within the 90 days of gestation, IVG was allowed only with surgical treatment.
The Ministry of Health on 12 August 2020 issued the circular "Guidelines on voluntary termination of pregnancy with mifepristone and prostaglandins", updating the previous one dated 24 June 2010.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients over 18 years of age
- •IVG certificate issued by the doctor and signed by the woman
- •Informed consent for drug treatment
- •Informed consent for the study in question
- •Pregnancy in utero with ultrasound date less than or equal to 63 days
排除标准
- •Suspected extrauterine pregnancy or adnexal masses of undefined diagnosis
- •IUD in place
- •Severe anaemia
- •Hereditary porphyria
- •Coagulopathy or ongoing treatment with anticoagulants
- •Ongoing treatment with corticosteroids or adrenal insufficiency
结局指标
主要结局
Pain symptoms of patients undergoing pharmacological IVG
时间窗: 48 hours after the administration of mifepristone and after an observation period of not less than 3 hours
Assessing the pain symptoms of patients undergoing pharmacological IVG recorded according to the Visual Analog Scale (VAS) scale and the need for additional analgesic therapy (rescue dose), in relation to certain variables such as the patient's age, gestational age, anxiety trait and pre-procedure anxiety state of the patients assessed by means of scientifically validated questionnaires. - VAS questionnaire: 0-100 numeric scale to record the patient's pain symptoms. 0 is considered the absence of pain, ≤ 40 tolerable pain (not requiring supplementary therapy), \> 40 ≤ 70 intense pain (responsive to required supplementary therapy), \> 70 intolerable pain not responsive to required supplementary therapy, 100 maximum pain perceived in the patient's life.
次要结局
- Patient satisfaction(48 hours after the administration of mifepristone and after an observation period of not less than 3 hours)